Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival
Autore:
Giatromanolaki, A; Koukourakis, MI; Sivridis, E; Turley, H; Talks, K; Pezzella, F; Gatter, KC; Harris, AL;
Indirizzi:
John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Mol Oncol Labs,Oxford OX3 9DS, England John Radcliffe Hosp Oxford England OX3 9DS Labs,Oxford OX3 9DS, England Democritus Univ Thrace, Dept Pathol, Alexandroupolis 68100, Greece Democritus Univ Thrace Alexandroupolis Greece 68100 upolis 68100, Greece Democritus Univ Thrace, Dept Radiotherapy Oncol, Alexandroupolis 68100, Greece Democritus Univ Thrace Alexandroupolis Greece 68100 upolis 68100, Greece John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 7LJ, England John Radcliffe Hosp Oxford England OX3 7LJ Sci, Oxford OX3 7LJ, England
Titolo Testata:
BRITISH JOURNAL OF CANCER
fascicolo: 6, volume: 85, anno: 2001,
pagine: 881 - 890
SICI:
0007-0920(20010914)85:6<881:ROHIF1>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENDOTHELIAL GROWTH-FACTOR; HUMAN ERYTHROPOIETIN GENE; PAS DOMAIN PROTEIN-1; THYMIDINE PHOSPHORYLASE; EXPRESSION; ANGIOGENESIS; TRANSCRIPTION; OVEREXPRESSION; ACTIVATION; FACTOR-1-ALPHA;
Keywords:
non-small-cell lung cancer; hypoxia inducible factors; angiogenesis; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
48
Recensione:
Indirizzi per estratti:
Indirizzo: Harris, AL John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Mol Oncol Labs,Oxford OX3 9DS, England John Radcliffe Hosp Oxford England OX39DS d OX3 9DS, England
Citazione:
A. Giatromanolaki et al., "Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival", BR J CANC, 85(6), 2001, pp. 881-890

Abstract

Hypoxia inducible factors HIF1 alpha and HIF2 alpha are important proteinsinvolved in the regulation of the transcription of a variety of genes related to erythropoiesis, glycolysis and angiogenesis. Hypoxic stimulation results in rapid increase of the HIF1 alpha and 2 alpha. protein levels, as a consequence of a redox-sensitive stabilization. The HIF alphas enter the nucleus, heterodimerize with the HIF1 beta protein, and bind to DNA at the hypoxia response elements (HREs) of target genes. In this study we evaluated the immunohistochemical expression of these proteins in 108 tissue samples from non-small-cell lung cancer (NSCLC) and in normal lung tissues. Both proteins showed a mixed cytoplasmic/nuclear pattern of expression in cancer cells, tumoural vessels and tumour-infiltrating macrophages, as well as in areas of metaplasia, while normal lung components showed negative or very weak cytoplasmic staining. Positive HIF1 alpha and HIF2 alpha expression was noted in 68/108 (62%) and in 54/108 (50%) of cases respectively. Correlation analysis of HIF2 alpha expression with HIF1 alpha expression showed a significant association (P < 0.0001, r = 0.44). A strong association of the expression of both proteins with the angiogenic factors VEGF (P < 0.004), PD-ECG F (P < 0.003) and bFGF (P < 0.04) was noted. HIF1 alpha correlated withthe expression of bek-bFGF receptor expression (P = 0.01), while HIF2 alpha was associated with intense VEGF/KDR-activated vascularization (P = 0.002). HIF2 alpha protein was less frequently expressed in cases with a medium microvessel density (MVD); a high rate of expression was noted in cases with both low and high MVD (P = 0.006). Analysis of overall survival showed that HIF2a expression was related to poor outcome (P = 0.008), even in the group of patients with low MVD (P = 0.009). HIF1 alpha expression was marginally associated with poor prognosis (P = 0.08). In multivariate analysis HIF2 alpha expression was an independent prognostic indicator (P = 0.006, t-ratio 2.7). We conclude that HIF1 alpha and HIF2 alpha overexpression is a common event in NSCLC, which is related to the up-regulation of various angiogenic factors and with poor prognosis. Targeting the HIF pathway may prove of importance in the treatment of NSCLC. (C) 2001 Cancer Research Campaign.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 05:00:46